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CORRESPONDENCE
Arcanobacterium hemolyticum: identification
and susceptibility to nine antimicrobial agents
Arcanobacterium hemolyticum is a b-hemolytic
Gram-positive, pleomorphic, facultative anaerobic,
non-acid-fast rod that has been implicated as an
etiologic agent of non-streptococcal pharyngitis,
especially in adolescents and young adults, as well
as a cause of skin andwound infections, osteomye-
litis, sepsis, and central nervous system infections.
We describe 19 strains of A. hemolyticum that
were isolated during a period of two years (1998–
2000) from human sources, their microbiological
features, and their antimicrobial susceptibility.
The samples were cultured on Columbia agar
(Difco, Detroit, Michigan, USA) with 5% human
blood for 24–48 h at 35 8C in an aerobic atmosphere.
Identiﬁcation was achieved using morphology
of colonies, Gram stain and biochemical tests,
following the scheme of vonGraevenitz and Funke
[1], API Coryne (bioMe´rieux SA, Marcy L0 Etoile,
France), and additional tests such as PYR, produc-
tion of a-mannosidase (RoscoDiagnostic, Taastrup,
Denmark), and bacitracin susceptibility (0.04U)
(Laboratory Britania, Argentina). Any strain with
a zone of inhibited growth around the bacitracin
disk was considered to be susceptible for iden-
tiﬁcation purposes.
Antigenic characteristics were determined by
extraction of cells by the Lanceﬁeld extraction
procedure and reaction with antisera for groups
A, B, C, D, F and G (bioMe´rieux SA).
The CAMP reaction was performed with a b-
hemolytic strain of Staphylococcus aureus (ATCC
25923) and with a group B b-hemolytic streptococ-
cus.
The following antimicrobial agents were tested:
penicillin, cephalothin cefuroxime, erythromycin,
azithromycin, tetracycline, clindamycin, ciproﬂox-
acin, and vancomycin. The MICs were determined
by an agar dilution method on Mueller–Hinton
agar supplemented with 5% sheep blood. S. aureus
ATCC 29213 and Enterococcus faecalis ATCC 29212
were used as quality control strains.
Because of the absence of accepted breakpoints
for A. hemolyticum, those established by the
NCCLS for organisms that grow aerobically were
used [2].
Thirteen strains were isolated from the throat,
and others from diabetic foot ulcers, bone, urethral
discharge, peritonsillar abscess, pleural ﬂuid, and
lochia. Three of the infections were mixed, with
the following organisms being simultaneously iso-
lated: frompleural ﬂuid of a patientwith traumatic
hemothorax, Streptococcus agalactiae and group G
Streptococcus dysgalactiae subsp. equisimilis; from
urethral discharge, Gardnerella vaginalis and anae-
robic ﬂora; and from lochia from spontaneous
abortion, Escherichia coli.
None of the throat samples yielded b-hemolytic
streptococci, including A. hemolyticum.
Antimicrobial susceptibility results are shown
in Table 1.
Discrepant PYR results were obtained between
API Coryne and PYR tests based on commercial
disks. Whereas 13 strains gave positive PYR tests
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Antimicrobial
agent
No. of
susceptible
strains/Total
(% susceptible
strains)a
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Penicillin 18/19 (94.7)b 0.004–0.25 0.016
19/19 (100)c 0.064
Cephalothin 19/19 (100) 0.004–0.064 0.016 0.032
Cefuroxime 19/19 (100) 0.032–0.5 0.125 0.25
Erythromycin 19/19 (100) 0.004–0.25 0.004 0.032
Azithromycin 19/19 (100) < 0.004 < 0.004 < 0.004
Tetracycline 13/19 (68) 0.25–64 0.5 32
Clindamycin 19/19 (100) 0.004–0.032 0.008 0.016
Ciprofloxacin 19/19 (100) 0.25–0.5 0.25 0.5
Vancomycin 19/19 (100) 0.25–0.5 0.25 0.5
aAccording to NCCLS interpretative standards (2000). bThe category for
staphylococci was applied. cThe category for Listeria monocytogenes was applied.
Table 1 Antimicrobial susceptibility
of 19 strains of Arcanobacterium
hemolyticum
with disks, only six gave positive PYR tests with
API Coryne.
Bacitracin inhibition zone diameters around the
disks were between 8 and 14mm.
The codes obtained by the API Coryne identi-
ﬁcation system were 2010360, 2110360, 2130360,
2210360, 2230360, 2310360, 2510360, 2530360,
6010360, 6110360, 6130360, 6330360 and 6530361,
giving good, very good or excellent identiﬁcation
as A. hemolyticum.
The clinical picture of A. hemolyticum is indis-
tinguishable from that of streptococcal pharyngi-
tis, and since all strains were susceptible to
bacitracin, and 13 of 19 were PYR test positive
using commercial disks, we consider that a Gram
stain should always be performed on throat sam-
ples to differentiate Streptococcus pyogenes. Further-
more, all the strains showed cross-agglutination
with antisera for groups A, B, C, D, F or G.
All strains were a-mannosidase positive, as
reported by Carlson and Kontiainen [3].
All the strains were CAMP positive when the
test was performed by streaking S. agalactiae
according to the method of Lammer and Blobel
[4], and reverse CAMP positive when using S.
aureus ATCC 25923.
A. hemolyticum was susceptible to penicillin
(MIC90 0.064mg/L).
Even though most of the strains were inhibited
by 0.064mg/L, the MIC was 0.25mg/L for one
strain. Clinical failures that have been reported
could be associated with penicillin tolerance [5].
All clinical isolates were susceptible to cepha-
losporins. The MICs of cephalothin were lower
than those of cefuroxime. The MIC90s were
0.032mg/L and 0.25mg/L, respectively.
The strains were susceptible to vancomycin
(MIC90 0.5mg/L), as has been reported by Carlson
et al. [5]. However, a single A. hemolyticum strain
carrying the vanA gene conferring resistance to
vancomycin has been reported by Power et al. [6].
Six of 19 strains were resistant to tetracycline, as
has been described in other reports [5].
Virtually allA. hemolyticum strains studied so far
have been susceptible to erythromycin, azithro-
mycin and clindamycin, but one macrolide-resis-
tant A. hemolyticum strain has been reported by
Carlson et al. [5].
In conclusion, a Gram-positive rod that exhibits
b-hemolysis on human blood agar, that is catalase
negative, and gives a positive result with the
CAMP test and reverse CAMP test using S. aga-
lactiae and S. aureusATCC 25923, respectively, may
be identiﬁed as A. hemolyticum. Only tetracycline
showed variable activity against the strains.
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